Seattle, WA — September 4, 2025 — Leads & Copy — Pluristyx Inc. and BioLamina AB have announced a strategic partnership to co-develop and co-market solutions aimed at simplifying and accelerating the clinical translation of induced pluripotent stem cell (iPSC)-based therapies.
The collaboration will combine Pluristyx’s iPSC platform with BioLamina’s Biolaminin® matrices to provide a streamlined workflow for researchers and developers. The companies will engage in joint marketing activities to offer validated solutions for cell therapy programs, addressing key manufacturing challenges in regenerative medicine.
Benjamin Fryer, PhD, CEO of Pluristyx, stated that the partnership is a critical step toward empowering the development of next-generation cell therapies. Therése Kallur, PhD, CSBDO of BioLamina, added that the collaboration will enable a seamless workflow that meets the demands of clinical translation.
The partnership will focus on creating optimized culture systems to ensure high cell quality and reproducibility, meeting regulatory requirements.
Media Contacts:
Pluristyx
Dr. Priya Baraniak
Chief Commercial and Development Officer
priya@pluristyx.com
BioLamina
Elin Persson
Marketing Manger
Elin.persson@biolamina.com
Source: Pluristyx Inc.
